BLAINJECTIONSOLUTIONPriority Review
Approved
Oct 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INMAZEB is a triple monoclonal antibody cocktail (atoltivimab, maftivimab, and odesivimab-ebgn) administered as an intravenous injection to treat Ebola virus disease (EVD). The three antibodies target different epitopes on the Ebola virus glycoprotein to provide broad neutralization and viral clearance.
Peak
Niche indication limits volume, but peak status and Regeneron backing create stable specialized roles in medical affairs, regulatory, and procurement for rare disease expertise.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Started Jan 2027
132 enrolled
Ebola Virus Disease
Career Relevance
Working on INMAZEB offers career visibility in regulatory excellence, rare disease strategy, and government partnerships, with roles concentrated in compliance, medical leadership, and procurement. This is a specialized niche within Regeneron suited for professionals seeking deep expertise in outbreak preparedness and humanitarian medicine rather than high-volume commercial growth.
Manager
Worked on INMAZEB at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.